ITOS (iTeos Therapeutics) Total Enterprise Value

iTeos Therapeutics focuses on developing targeted antibodies to combat cancer, expanding its drug portfolio in collaboration with market leaders. Simultaneously, the business implements ESG environmental standards and strictly adheres to bioethical guidelines. The linear price action on the GURU.Markets chart shows an Enterprise Value of , while research efficiency is driven by the robotization of laboratory testing.

To isolate fundamental stability from market noise, capital utilizes Enterprise Value, which sums market capitalization and debt minus cash, to determine the total cost of acquiring a business. By analyzing the Enterprise Value trend on GURU.Markets, an investor assesses the real price of iTeos Therapeutics (ITOS), whose value is supported by the recruitment of leading immuno-oncologists and the development of innovative platforms in the US and Belgium.